Yazen Closes a 19.5 Million Round to Grow and Expand Internationally

Yazen raises double-digit capital. The healthcare company specialising in comprehensive obesity treatment through a digital platform has announced the closing of an oversubscribed Series A financing round of 19.5 million euros . With this money, the company will strengthen its position as an operator in the treatment of obesity and reinforce its international expansion plans.

The funding round was co-led by Finland’s Evli Growth Partners and Switzerland’s Helsana HealthInvest , with participation from Germany’s Almaz Capital and Yabeo. Yazen also has the support of Swedish investors Luminar Ventures and Aggregate Media in this funding round.

The new funding will serve to further scale the business internationally. Following the success achieved in Sweden and the start of activity in Germany and the United Kingdom as pilot markets, Yazen now aims to expand into Spain, Norway and the Netherlands .

Yazen aims to triple its growth in the next two to three years

The company has ambitious plans to triple its growth over the next two to three years, focusing on improving its offering, strengthening its organisation and expanding in these countries.

The investment will also allow for further development of the Yazen app and its comprehensive care service, designed to better support patients. Yazen offers a multidisciplinary care model where patients receive support from a specialised team of doctors, coaches , psychologists, dieticians and personal trainers, providing a complete solution that is reflected in the excellent user feedback and engagement.

As a result of the funding round, Yazen welcomes Mikael Hed, Founding Partner of Evli Growth Partners and former CEO of Rovio (creators of Angry Birds), as the new Chairman of the Board. His experience in building and scaling an international brand will be a highly valuable asset for Yazen in its next phase of growth.

__

(Featured image by AllGo via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us